Document:

QuickLinks
 -- Click here to rapidly navigate through this document

 

 
 

  Exhibit 10.14.2    
    

			
	Notice of Grant of Stock Options

and Option Agreement	 	 GENZYME CORPORATION
 ID: 06-1047163

500 Kendall Street

Cambridge, MA 02142

 

 

					
	[First Name][Family Name]

[Address Line 1]

[City], [State] [Postal Code]	 	Option Number:

Plan:

ID:	 	[00000000]

[####]

[SSN or Emp. ID]]

Effective
[Date], you have been granted a Non-Statutory Stock Option to buy [#,####] shares of GENZYME CORPORATION (the Company) stock at
$[Value] per share. 

The
total option price of the shares granted is $[Value]. 

Shares
in each period will become fully vested on the date shown. 

							
	Shares

 
	 	Vest Type 	 	Full Vest 	 	Expiration 
	[#,###]	 	On Vest Date	 	[Date]	 	[Date]
	[#,###]	 	On Vest Date	 	[Date]	 	[Date]
	[#,###]	 	On Vest Date	 	[Date]	 	[Date]
	[#,###]	 	On Vest Date	 	[Date]	 	[Date]
	[#,###]	 	On Vest Date	 	[Date]	 	[Date]

MAINTAIN
THIS COPY FOR YOUR RECORDS. 

These
options are granted under and governed by the terms and conditions of the Company's Stock Option plan as amended and the Option Agreement, all of which are attached and made a part of this
document. 

 
 

  GENZYME CORPORATION 2004 EQUITY INCENTIVE PLAN
  OFFICER (TIER I)
  NONSTATUTORY STOCK OPTION AGREEMENT    
    

        1.    Plan Incorporated by Reference.    This Option is issued pursuant to the terms of the Plan, as amended or may be
amended, and this Nonstatutory Stock Option Agreement ("Agreement"), and may be amended as provided in the Plan. Capitalized terms used and not otherwise defined in this Agreement have the meanings
given to them in the Plan. This Agreement does not set forth all of the terms and conditions of the Plan, which are incorporated herein by reference. The Committee administers the Plan and its
determinations regarding the operation of the Plan are final and binding. Copies of the Plan may be obtained upon written request without charge from the Shareholder Relations Department of the
Company. 

        2.    Option Price.    The price to be paid for each share of Common Stock issued upon exercise of the whole or any
part of this Option (the "Option Price") is the option price set forth in the Notice of Grant of Stock Options associated with this Agreement ("Notice"). 

        3.    Exercisability Schedule.    This Stock Option will vest in accordance with the exercisability schedule set forth
in the Notice, provided that Participant is continuously employed with the Company or an Affiliate through each applicable date set forth in such schedule, except as otherwise specified herein. This
Option may be exercised for the purchase of only whole shares at any time and from time to time up to the number of shares vested per such schedule set forth. This Option may not be exercised as to
any shares after the date of expiration set forth in the Notice. 

        4.    Method of Exercise.    To exercise this Option, the Participant shall deliver written notice of exercise to the
Company specifying the number of shares with respect to which the Option is being exercised accompanied by payment of the Option Price for such shares in cash, by certified check or in such other
form, including shares of Common Stock of the Company valued at their Fair Market Value on the date of delivery, as the Committee may approve. Promptly following such notice, the Company will deliver
to the Participant a certificate representing the number of shares with respect to which the Option is being exercised. 

        5.    Recapitalization, Mergers, Etc.    In the event of a consolidation or merger of the Company with another entity,
the sale or exchange of all or substantially all of the assets of the Company or a reorganization or liquidation of the Company, the Committee may upon written notice to the Participant provide that
this Option shall terminate on a date not less than 20 days after the date of such notice unless theretofore exercised. In connection with such notice, the Committee may in its discretion
accelerate or waive any deferred exercise period. Notwithstanding the foregoing, in the event of a change in control of the Company (as defined in the Participant's employment agreement), this Option
shall become exercisable as to all shares without regard to any deferred exercisability schedule or deferred exercise period. 

        6.    Transferability.    This Option may be transferred without consideration (or for such consideration as the
Committee may from time to time deem appropriate) by the holder thereof to any Family Member; provided, however, that no subsequent transfer of such option shall be permitted except for transfers:
(i) to a Family Member; (ii) back to the Participant; or (iii) pursuant to the applicable laws of descent and distribution. For this purpose, "Family Member" shall mean
(i) any child, stepchild, grandchild,
parent, stepparent, grandparent, spouse, former spouse, sibling, niece, nephew, mother-in-law, father-in-law, son-in-law,
daughter-in-law, brother-in-law or sister-in-law, including any adoptive relationships, and any other person sharing the
Participant's household (other than as a tenant or employee); (ii) any trust in which any of the persons described in clause (i) holds a greater than 50% beneficial interest;
(iii) any foundation in which any of the persons described in clause (i) or the Participant controls the management of assets; or (iv) any other entity in which any of the persons
described in clause (i) or the Participant holds more than 50% of the voting interests. 

        7.    Exercise of Option After Termination of Employment.    If the Participant's employment with (a) the
Company, (b) an Affiliate, or (c) a corporation (or parent or subsidiary corporation of such 

corporation)
issuing or assuming a stock option in a transaction to which section 424(a) of the Code applies, is terminated for any reason other than by the Company without cause; by the
Company as a result of disability (as defined in the Participant's employment agreement); due to death or after having achieved retirement status (defined as a minimum of age 60  plus a minimum of five
years of service provided termination is not for cause), the Participant may exercise the rights that were available to the
Participant at the time of such termination only within three months from the date of termination. If Participant's employment is terminated by the Company without cause, this Option shall become
exercisable as to all shares without regard to any deferred exercise period, and such rights may be exercised within three months from the date of termination. If Participant's employment is
terminated as a result of disability, this Option shall become exercisable as to all shares without regard to any deferred exercise period, and such rights may be exercised within twelve months from
the date of termination. Upon the death of the Participant, this Stock Option shall become exercisable as to all shares without regard to any deferred exercise period, and his or her Designated
Beneficiary shall have the right, at any time within twelve months after the date of death, to exercise such rights. Notwithstanding the foregoing three sentences, if the Participant has achieved
retirement status as of the date of termination for any reason (including death and disability) except for cause, this Stock Option shall become exercisable as to all shares without regard to any
deferred exercise period, and such rights may be exercised within three years from the date of termination. Termination by the Company of the Participant's employment for "cause" shall mean
termination upon (A) the willful and continued failure by him or her to substantially perform his or her duties with the Company (other than any such failure resulting from his or her
incapacity due to physical or mental illness) after a written demand for substantial performance is delivered to the Participant by the Company, which demand specifically identifies the manner in
which the Company believes that he or she has not substantially performed his or her duties, or (B) the willful engaging by the Participant in conduct which is demonstrably and materially
injurious to the Company, monetarily or otherwise. No act, or failure to act, on the Participant's part shall be deemed "willful" unless done, or omitted to be done, by him or her not in good faith
and without reasonable belief that his or her action or omission was in the best interest of the Company. In the case of any Participant who is a corporate officer of the Company, determination for
purposes of this section of whether termination of such Participant's employment is for "cause" shall be made by the Committee. In the case of any Participant who is not a corporate officer of the
Company, determination for purposes of this section of whether termination of such Participant's employment is for "cause" shall be made by the Senior Vice President, Chief Human Resources Officer, in
his sole discretion, whose decision shall be final. 

        8.    Compliance with Securities Laws.    It shall be a condition to the Participant's right to purchase shares of
Common Stock hereunder that the Company may, in its discretion, require (a) that the shares of Common Stock reserved for issue upon the exercise of this Option shall have been duly listed, upon
official notice of issuance, upon any national securities exchange or automated quotation system on which the Company's Common Stock may then be listed or quoted, (b) that either (i) a
registration statement under the Securities Act of 1933 with respect to the shares shall be in effect, or (ii) in the opinion of counsel for the Company, the proposed purchase shall be exempt
from registration under that Act and the Participant shall have made such undertakings and agreements with the Company as the Company may reasonably require, and (c) that such other steps, if
any, as counsel for the Company shall consider necessary to comply with any law applicable to the issue of such shares by the Company shall have been taken by the Company or the Participant, or both.
The certificates representing the shares purchased under this Option may contain such legends as counsel for the Company shall consider necessary to comply with any applicable law. 

        9.    Payment of Taxes.    The Participant shall pay to the Company, or make provision satisfactory to the Company for
payment of any taxes required by law to be withheld with respect to the exercise of this Option. The Committee may, in its discretion, require any other federal or state taxes imposed on the sale of
the shares to be paid by the Participant. In the Committee's discretion, such tax obligations may be paid in whole or in part in shares of Common Stock, including shares retained from the exercise of
this Option, valued at their Fair Market Value on the date of delivery. The Company and its 

Affiliates
may, to the extent permitted by law, deduct any such tax obligations from any payment of any kind otherwise due to the Participant. 

        10.    Rights Limited.    The Committee, in its sole discretion, shall determine from the group of eligible persons
whether an individual shall be a Participant under the Plan. Any Option grant made under the Plan shall be made in the sole discretion of the Committee, or its delegate as appointed in accordance with
the Plan, and no prior Option grant shall entitle a person to any future Award. In no event shall the Plan, or any Option grant made under the Plan, form a part of an employee's or consultant's
contract of employment or service, if any. Neither the Plan, nor any Option grant made under the Plan, shall confer upon any employee or consultant of the Company or its Affiliate any right with
respect to the continuance of his or her employment by, or other service with, the Company or its Affiliate, nor shall they limit the rights of the Company or its Affiliate to terminate the employee
or consultant or otherwise change the terms of service. No Participant or Designated Beneficiary shall have any rights as a shareholder with respect to any shares of Common Stock to be issued under
the Plan or any Option until he or she becomes the holder thereof. The loss of existing or potential profit in an Option grant shall not constitute an element of damages in the event of termination of
employment or service for any reason, even if the termination is in violation of an obligation of the Company or its Affiliate to the Participant. 

        11.    Acceptance.    Failure of the Participant to accept the terms and conditions of this Option in accordance with
the requirements of the Committee or its delegate, as applicable, can result in adverse consequences to the Participant, including cancellation of the Option. 

			
	ACKNOWLEDGED AND AGREED:	 	 
	

  Participant Signature	
 	

 
	

  Participant Name (Print)	
 	

 
	

  Date	
 	

 

 
 

  GENZYME CORPORATION 2004 EQUITY INCENTIVE PLAN
  Officer (Tier II)
  Nonstatutory Stock Option Agreement    
    

        1.    Plan Incorporated by Reference.    This Stock Option is issued pursuant to the terms of the Plan, as amended or
may be amended, and this Nonstatutory Stock Option Agreement ("Agreement"), and may be amended as provided in the Plan. Capitalized terms used and not otherwise defined in this Agreement have the
meanings given to them in the Plan. This Agreement does not set forth all of the terms and conditions of the Plan, which are incorporated herein by reference. Copies of the Plan may be obtained upon
written request without charge from the Shareholder Relations Department of the Company. 

        2.    Option Price.    The price to be paid for each share of Stock issued upon exercise of the whole or any part of
this Stock Option (the "Option Price") is the option price set forth in the Notice of Grant of Stock Options associated with this Agreement ("Notice"). 

        3.    Exercisability Schedule.    This Stock Option will vest in accordance with the exercisability schedule set forth
in the Notice, provided that Participant is continuously employed with the Company or an Affiliate through each applicable date set forth in such schedule, except as otherwise specified herein. This
Stock Option may be exercised for the purchase of only whole shares at any time and from time to time up to the number of shares vested per such schedule. Notwithstanding anything in this Agreement,
this Stock Option may not be exercised as to any shares after the date of expiration set forth in the Notice. 

        4.    Method of Exercise.    To exercise this Stock Option, the Participant shall deliver written notice of exercise
to the Company specifying the number of shares with respect to which the Stock Option is being exercised accompanied by payment of the Option Price for such shares in cash, by certified check or in
such other form, including shares of Stock of the Company valued at their Fair Market Value on the date of delivery, as the Administrator may approve. Promptly following such notice, the Company will
deliver to the Participant a certificate representing the number of shares with respect to which the Stock Option is being exercised. 

        5.    Recapitalization, Mergers, Etc.    In the event of a Covered Transaction, the Administrator may upon written
notice to the Participant provide that this Stock Option shall terminate on a date not less than 20 days after the date of such notice unless theretofore exercised. In connection with such
notice, the Administrator may in its discretion accelerate or waive any deferred exercise period. Notwithstanding the foregoing, in the event of a change in control of the Company (as defined in a
vote of the Compensation Committee adopted May 29, 2002), this Stock Option shall become exercisable as to all shares without regard to any deferred exercisability schedule or deferred exercise
period. 

        6.    Transferability.    This Stock Option may be transferred without consideration (or for such consideration as the
Administrator may from time to time deem appropriate) by the holder thereof to any Family Member; provided, however, that no subsequent transfer of such option shall be permitted except for transfers:
(i) to a Family Member; (ii) back to the Participant; or (iii) pursuant to the applicable laws of descent and distribution. For this purpose, "Family Member" shall mean
(i) any child, stepchild, grandchild, parent, stepparent, grandparent, spouse, former spouse, sibling, niece, nephew, mother-in-law,
father-in-law, son-in-law, daughter-in-law, brother-in-law or sister-in-law,
including any adoptive relationships, and any other person sharing the Participant's household (other than as a tenant or employee); (ii) any trust in which any of the persons described in
clause (i) holds a greater than 50% beneficial interest; (iii) any foundation in which any of the persons described in clause (i) or the Participant controls the management of
assets; or (iv) any other entity in which any of the persons described in clause (i) or the Participant holds more than 50% of the voting interests. 

        7.    Exercise of Stock Option After Termination of Employment.    If the Participant's employment with (a) the
Company, (b) an Affiliate, or (c) a corporation (or parent or subsidiary corporation of such corporation) issuing or assuming a stock option in a transaction to which
section 424(a) of the 

Code
applies, is terminated for any reason other than by the Company as a result of disability (within the meaning of section 22(e)(3) of the Code); due to death; or after having achieved
retirement status (defined as a minimum of age 60 plus a minimum of five years of service provided termination is not for cause), the Participant may
exercise the rights that were available to the Participant at the time of such termination only within three months from the date of termination. If Participant's employment is terminated as a result
of disability, this Stock Option shall become exercisable as to all shares without regard to any deferred exercise period, and such rights may be exercised within twelve months from the date of
termination. Upon the death of the Participant, this Stock Option shall become exercisable as to all shares without regard to any deferred exercise period, and his or her Designated Beneficiary shall
have the right, at any time within twelve months after the date of death, to exercise such rights. Notwithstanding the foregoing two sentences, if the Participant has achieved retirement status as of
the date of termination for any reason (including death and disability) except for cause, this Stock Option shall become exercisable as to all shares without regard to any deferred exercise period,
and such rights may be exercised within three years from the date of termination. If the Participant's employment is terminated for cause, the Participant may exercise the rights which were available
to the Participant at the time of such termination only within three months from the date of termination. Termination by the Company of the Participant's employment for "cause" shall mean termination
upon (A) the willful and continued failure by him or her to substantially perform his or her duties with the Company (other
than any such failure resulting from his or her incapacity due to physical or mental illness) after a written demand for substantial performance is delivered to the Participant by the Company, which
demand specifically identifies the manner in which the Company believes that he or she has not substantially performed his or her duties, or (B) the willful engaging by the Participant in
conduct which is demonstrably and materially injurious to the Company, monetarily or otherwise. No act, or failure to act, on the Participant's part shall be deemed "willful" unless done, or omitted
to be done, by him or her not in good faith and without reasonable belief that his or her action or omission was in the best interest of the Company. In the case of any Participant who is a corporate
officer of the Company, determination for purposes of this section of whether termination of such Participant's employment is for "cause" shall be made by the Committee. In the case of any Participant
who is not a corporate officer of the Company, determination for purposes of this section of whether termination of such Participant's employment is for "cause" shall be made by the Senior Vice
President, Chief Human Resources Officer, in his sole discretion, whose decision shall be final. A "Designated Beneficiary" means the beneficiary designated by the Participant, in a manner determined
by the Administrator, to receive amounts due or exercise rights of the Participant in the event of the Participant's death. In the absence of an effective designation by the Participant, "Designated
Beneficiary" means the Participant's estate. 

        8.    Payment of Taxes.    The Participant shall pay to the Company, or make provision satisfactory to the Company for
payment of any taxes required by law to be withheld with respect to the exercise of this Stock Option. The Administrator may, in its discretion, require any other federal or state taxes imposed on the
sale of the shares to be paid by the Participant. In the Administrator's discretion, such tax obligations may be paid in whole or in part in shares of Stock, including shares retained from the
exercise of this Stock Option, valued at their Fair Market Value on the date of delivery. The Company and its Affiliates may, to the extent permitted by law, deduct any such tax obligations from any
payment of any kind otherwise due to the Participant. 

        9.    Rights Limited.    The Administrator, in its sole discretion, shall determine from the group of eligible persons
whether an individual shall be a Participant under the Plan. Any grant made under the Plan shall be made in the sole discretion of the Administrator and no prior grant shall entitle a person to any
future grant. Nothing in the Plan or any Stock Option grant will be construed as giving any person the right to continued employment or service with the Company or its Affiliates, or any rights as a
shareholder except as to shares of Stock actually issued under the Plan. In no event shall the Plan, or any grant made under the Plan, form a part of an employee's or consultant's contract of
employment or service, if any. The loss of existing or potential profit in Stock Options will not constitute an element of damages in the event of termination of employment or service for any reason,
even if the termination is in violation of an obligation of the Company or Affiliate to the Participant. 

        10.    Acceptance.    Failure of the Participant to accept the terms and conditions of this Stock Option in accordance
with the requirements of the Administrator can result in adverse consequences to the Participant, including cancellation of the Stock Option. 

			
	ACKNOWLEDGED AND AGREED:	 	 
	

  Participant Signature	
 	

 
	

  Participant Name (Print)	
 	

 
	

  Date	
 	

 

QuickLinks

Exhibit 10.14.2

GENZYME CORPORATION 2004 EQUITY INCENTIVE PLAN OFFICER (TIER I) NONSTATUTORY STOCK OPTION AGREEMENT

GENZYME CORPORATION 2004 EQUITY INCENTIVE PLAN Officer (Tier II) Nonstatutory Stock Option AgreementQuickLinks
 -- Click here to rapidly navigate through this document

 

 
 

  Exhibit 10.16    
    

 
 

  GENZYME CORPORATION DIRECTORS' DEFERRED
  COMPENSATION PLAN    
    

 ARTICLE I  

 GENERAL  

        1.1    Establishment of Plan.    Genzyme Corporation ("Genzyme") established the Genzyme Directors' Deferred
Compensation Plan (the "plan"), effective as of May 16, 1996, to allow each member of the Genzyme Board of Directors who is not also an officer or employee of Genzyme or its subsidiaries (an
"outside director") to defer receipt of all or a portion of the cash compensation payable to him or her as such a director of Genzyme until (i) with respect to compensation earned prior to
January 1, 2005, the termination of his or her service as a director, or (ii) with respect to compensation earned on or after January 1, 2005, his or her Termination of Service as
defined in Section 3.8, or (iii) with respect to compensation whenever earned, but subject to the requirements set forth in Section 3.1, such other date
as may be specified by the director. The plan as set forth below was amended and restated effective December 1, 2008. 

        1.2    No Right to Corporate Assets.    The plan is unfunded and Genzyme will not be required to set aside, segregate,
or deposit any funds or assets of any kind to meet its obligations hereunder. Nothing in the plan will give a participant, a participant's beneficiary or any other person any equity or other interest
in the assets of Genzyme, or create a trust of any kind or a fiduciary relationship of any kind between Genzyme and any such person. Any rights that a participant, beneficiary or other person may have
under the plan will be solely those of a general unsecured creditor of Genzyme. 

        1.3    Limitation on Rights Created by Plan.    Nothing in the plan will give a participant any right to continue as a
director of Genzyme. 

        1.4    Nonalienation of Benefits.    The rights and benefits of a participant in the plan are personal to the
participant. No interest, right or claim under the plan and no distribution therefrom will be assignable, transferable or subject to sale, mortgage, pledge, hypothecation, anticipation, garnishment,
attachment, execution or levy, except by designation of beneficiaries as provided in Section 3.5. 

        1.5    Binding Effect of Plan.    The plan will be binding upon and inure to the benefit of participants and
designated beneficiaries and their heirs, executors and administrators, and to the benefit of Genzyme and its assigns and successors in interest. 

        1.6    Administration.    The plan will be administered by the Secretary of Genzyme, who will have sole responsibility
for its interpretation. 

        1.7    Interpretation.    The plan will be construed, enforced and administered according to the laws of the
Commonwealth of Massachusetts. 

 ARTICLE II  

 DEFERRAL OF COMPENSATION  

        2.1    Deferral Agreement.    Any active outside director (a "participant") is eligible to participate in the plan.
For compensation earned on or after January 1, 2005, the following deferral election rules shall apply: 

        (a)    Existing Outside Directors.    A participant may participate in the plan by executing an agreement before the
first day of any calendar year (beginning on or after January 1, 2005) in which such agreement will take effect authorizing Genzyme to defer all or a portion of his or her compensation as
director (the "deferral agreement"). A deferral agreement will become effective for compensation earned in the immediately following calendar year and remain in effect for 

compensation
earned in each succeeding calendar year unless the participant files a written revocation or superseding deferral agreement with the Secretary before the date that the deferral
agreement is irrevocable. A deferral agreement for any particular year is irrevocable after the last day of the immediately preceding calendar year. 

        (b)    New Outside Directors.    An individual who becomes a participant for the first time may participate in the
plan by executing an agreement within 30 days after the date that his or her term as an outside director begins, authorizing Genzyme to defer all or a portion of his or eligible compensation
during that calendar year as outside director (the "first-year deferral agreement"). A first-year deferral agreement will become effective for compensation earned beginning on
the 31st day after becoming an outside director unless the participant files a written revocation or superseding deferral agreement with the Secretary before the date that the
first-year deferral agreement is irrevocable. A first-year deferral agreement is irrevocable after 30 days following the date that an outside director's term begins.
After a first-year deferral agreement is effective, Section 2.1(a) applies for compensation earned in each succeeding calendar year. Whether an individual is eligible for the
first-year deferral rules of this Section 2.1(b) shall be determined in accordance with the regulations under Section 409A of the Internal Revenue Code of 1986, as amended
(the "Code" and "Section 409A"). 

        2.2    Amount of Deferral.    Each participant may elect in his or her deferral agreement to defer 25 percent,
50 percent, 75 percent or 100 percent of the total cash compensation paid to the participant as an outside director of Genzyme. 

        2.3    Deferral Account.    For bookkeeping purposes only, the Secretary will establish and maintain an account (the
"deferral account") for each participant that documents the compensation deferred by the participant, earnings credited to the account and payments from the account. The deferral account will consist
of a subaccount for amounts earning interest, which will be denominated on a dollar basis (the "cash account"), and a subaccount for amounts invested in hypothetical shares of Genzyme Common Stock,
$0.01 par value ("Genzyme Stock") which will be denominated on a share basis (the "stock account"). Each participant will indicate in his or her deferral agreement the percentage of future deferrals
to be invested in the cash account and the stock account. Amounts may not be transferred between the cash account and the stock account. 

        2.4    Cash Account.    As of the first day of each calendar quarter, the Secretary will credit to the participant's
cash account an amount equal to the amount of compensation otherwise payable to the participant in the preceding calendar quarter that the participant has elected to defer and invest in the cash
account. As of the last day of each calendar quarter, the Secretary will credit interest on the balance in the cash account on that date at the rate paid on 90-day Treasury bills
hypothetically purchased on the first day of such calendar quarter. For a participant receiving installment payments, interest will be credited on the balance from time to time remaining in the cash
account until the account has been completely paid. 

        2.5    Stock Account.    As of the first day of each calendar quarter, the Secretary will credit to the participant's
stock account a number of shares of Genzyme Stock equal to the amount of compensation otherwise payable to the participant in the preceding calendar quarter that the participant has elected to defer
and invest in Genzyme Stock divided by the stock price for Genzyme Stock. The stock price shall mean the average of the closing price of Genzyme Stock for all trading days during the preceding
calendar quarter as reported by the NASDAQ National Market. As of the date of payment of any cash dividend on Genzyme Stock, the Secretary will credit to the stock account a number of shares of
Genzyme Stock equal to (i) the cash dividend per share times the number of shares credited to the stock account as of the dividend record date divided by (ii) the closing price for
Genzyme Stock on the date of payment of the dividend. As of the date of payment of any stock dividend on Genzyme Stock, the Secretary will credit to the stock account a number of shares equal to the
per-share stock dividend declared times the number of shares of Genzyme Stock credited to the stock account as of the dividend record date. In the event of any stock dividend,
recapitalization, reorganization, merger, consolidation, split-up, spin-off, exchange of shares or similar change affecting Genzyme Stock, appropriate 

adjustment
will be made in the number and/or kind of shares credited to the stock account. The stock account is maintained for bookkeeping purposes only, and shares credited to the stock account
represent a notional investment only. Prior to distribution to a participant under Section 3.3 or 3.4, a participant will have no rights as a stockholder with respect to amounts credited to the
stock account. Shares will include fractional shares computed to three decimal places. 

        2.6    Shares Subject to the Plan.    The aggregate number of shares of Common Stock which may be issued under the
plan is 105,962 shares of Genzyme Stock. In the event of any stock dividend, split-up, combination or reclassification of shares, recapitalization or similar capital change relating to the
common stock, the maximum aggregate number and kind of shares or securities of Genzyme that may be issued under the plan shall be appropriately adjusted by the Genzyme Board of Directors (whose
determination shall be conclusive). 

 ARTICLE III  

 PAYMENT OF DEFERRED COMPENSATION  

        3.1    Commencement of Payment.    

        (a)    Compensation Earned Before January 1, 2005.    Each participant who participated in the plan with
respect to compensation earned before January 1, 2005 elected in his or her deferral agreement a payment commencement year that was to be either (i) the calendar year following his or
her termination of service as a director or (ii) another specified calendar year. If a participant elected a payment commencement year described in (ii) above, the earliest calendar year
that a participant could elect was the second calendar year following the year in which the election was made. Elections were irrevocable. 

        (b)    Compensation Earned On or After January 1, 2005.    With respect to compensation earned on or after
January 1, 2005, a participant must elect in his or her deferral agreement a payment commencement year that is either (i) the calendar year following his or her Termination of Service or
(ii) another specified calendar year. If a participant elects a payment commencement date described in (ii) above, the earliest calendar year that a participant may elect is the second
calendar year following the year in which the election is made. For example, a deferral agreement executed in 2008 may not specify a payment commencement date earlier than 2010. Any election under
this Section 3.1(b) will be irrevocable as described in Section 2.1. If an election under this Section 3.1(b) regarding the payment commencement date is not made or is invalid,
payments will commence in the calendar year after the year in which the participant's Termination of Service occurs and will be made in the applicable form of payment under Section 3.3(b) or
Section 3.4(b). 

        3.2    Election of Form of Payment.    

        (a)    Compensation Earned Before January 1, 2005.    Each participant who deferred compensation earned prior
to January 1, 2005 was required to elect in his or her deferral agreement to have his or her deferral account paid in either a lump sum or in annual installments for a period specified by the
participant not to exceed five years. 

        (b)    Compensation Earned On or After January 1, 2005.    With respect to compensation earned on or after
January 1, 2005, each participant must elect in his or her deferral agreement to have that portion of his or her deferral account attributable to such deferral paid in either a lump sum or in
annual
installments for a period specified by the participant not to exceed five years. Any election under this Section 3.1(b) will be irrevocable as described in Section 2.1. In the absence of
a valid election under this Section 3.1(b), payment will be made in a lump sum in accordance with Section 3.3(b). 

        3.3    Lump Sum Payments.    

        (a)    Compensation Earned Before January 1, 2005.    Lump sum payments of that portion of an account
attributable to a deferral of compensation earned prior to January 1, 2005 will be paid on or before March 1 of the year specified in the deferral agreement for commencement of payment. 

The
lump sum payment will consist of (i) cash in the amount credited to the distributable portion of the participant's cash account and (ii) the number of full shares of Genzyme Stock
credited to the distributable portion of the participant's stock account. No fractional shares will be issued under the plan, and the number of shares issued will be rounded down to the nearest full
share. 

        (b)    Compensation Earned On or After January 1, 2005.    Lump sum payments of that portion of an account
attributable to a deferral of compensation earned on or after January 1, 2005 will be paid on or after January 1 of the year specified in the deferral agreement for commencement of
payment. In the absence of a valid election under this Section 3.3(b), payment will be on or after January 1 of the year after Termination of Service. The lump sum payment will consist
of (i) cash in the amount credited to the distributable portion of the participant's cash account and (ii) the number of full shares of Genzyme Stock credited to the distributable
portion of the participant's stock account. No fractional shares will be issued under the plan, and the number of shares issued will be rounded down to the nearest full share. 

        3.4    Installment Payments.    

        (a)    Compensation Earned Before January 1, 2005.    Installment payments of that portion of an account
attributable to a deferral of compensation earned prior to January 1, 2005 will be made on or before March 1 of each year that installments are due, commencing with the year specified in
the participant's deferral agreement. Each installment payment will consist of (i) cash in the amount credited to the distributable portion of the participant's cash account on the date of
payment, divided by the number of annual installments remaining to be paid, and (ii) the number of full shares of Genzyme Stock credited to the distributable portion of the participant's stock
account, divided by the number of annual installments remaining to be paid. No fractional shares will be issued under the plan, and the number of shares issued will be rounded down to the nearest full
share. 

        (b)    Compensation Earned On or After January 1, 2005.    Installment payments of that portion of an account
attributable to a deferral of compensation earned on or after January 1, 2005 will be paid on or after
January 1 of each year that installments are due, commencing in the year specified in the participant's deferral agreement. In the absence of a valid election under this Section 3.4(b),
installment payments will commence in the year after Termination of Service. Each installment payment will consist of (i) cash in the amount credited to distributable portion of the
participant's cash account on the date of payment, divided by the number of annual installments remaining to be paid, and (ii) the number of full shares of Genzyme Stock credited to the
distributable portion of the participant's stock account, divided by the number of annual installments remaining to be paid. No fractional shares will be issued under the plan, and the number of
shares issued will be rounded down to the nearest full share. 

        3.5    Beneficiaries.    

        (a)    Compensation Earned Before January 1, 2005.    A participant may designate in his or her deferral
agreement a beneficiary or beneficiaries (which may be entities or natural persons) to receive any payments to be made upon his or her death with respect to deferrals of compensation earned prior to
January 1, 2005. A participant may elect to have payments to beneficiaries paid in a lump sum or in annual installments for a period not to exceed five years. At any time, and from time to
time, a participant may change or revoke his or her designation of beneficiary or form of payment without the consent of any beneficiary. Any such designation, change or revocation must be made in
writing and filed with the Secretary. If the participant designates more than one beneficiary, any payments to beneficiaries will be made in equal percentages unless the participant designates
otherwise. Any portion of a participant's deferral account that is not disposed of by designation of beneficiary upon the participant's death will be paid to his or her estate. 

        (b)    Compensation Earned On or After January 1, 2005.    With respect to deferrals of compensation earned on
or after January 1, 2005, a participant may designate in his or her deferral agreement a beneficiary or beneficiaries (which may be entities or natural persons) to 

receive
any payments to be made upon his or her death. All payments to designated beneficiaries will be made in single lump sum. At any time, and from time to time, a participant may change or revoke
his or her designation of beneficiary without the consent of any beneficiary. Any beneficiary designation, change, or revocation must be made in writing and filed with the Secretary. If the
participant designates more than one beneficiary, any payments to beneficiaries will be made in equal percentages unless the participant designates otherwise. Any portion of a participant's deferral
account that is not disposed of by designation of beneficiary upon the participant's death will be paid in a single lump sum to his or her estate. 

        3.6    Payments on Death.    

        (a)    Compensation Earned Before January 1, 2005.    If a participant dies before full payment of his or her
deferral account, Genzyme will make payments to the participant's designated beneficiary or
beneficiaries, or to his or her estate, of the amount remaining in that portion of the deceased participant's deferral account attributable to deferrals of compensation earned prior to
January 1, 2005. The payments will be in the form designated by the participant and will commence on the first day of the calendar quarter following the participant's death, or as soon as
practicable thereafter. Any remaining annual installments will be paid on or before March 1 of each succeeding year. 

        (b)    Compensation Earned On or After January 1, 2005.    If a participant experiences a Termination of
Service due to death before full payment of his or her deferral account, Genzyme will make a payment to the participant's designated beneficiary or beneficiaries, or to his or her estate, of the
amount remaining in that portion of the deceased participant's deferral account attributable to deferrals of compensation earned on or after January 1, 2005. The payments will be in a single
lump sum and will be made on the first day of the calendar quarter following the participant's death, or as soon as practicable thereafter. 

        3.7    Hardship Distributions from Accounts.    

        (a)    Compensation Earned Before January 1, 2005.    The Secretary may, in his or her discretion, distribute a
portion or all of that portion of a participant's cash account attributable to deferrals of compensation earned prior to January 1, 2005, in case of the participant's financial hardship. The
Secretary will determine the date of payment of the distribution. Hardship distributions are not permitted from a participant's stock account. 

        (b)    Compensation Earned On or After January 1, 2005.    The Secretary may, in his or her discretion,
distribute a portion or all of that portion of a participant's cash account attributable to deferrals of compensation earned on or after January 1, 2005, in case of the participant's financial
hardship due to "unforeseeable emergency" as defined in Section 409A(a)(2)(B)(ii)(I) of the Internal Revenue Code of 1986, as amended (the "Code"), and
Section 1.409A-3(i)(3)(i) of the Treasury Regulations ("Treas. Reg."). The Secretary shall have complete discretion, subject to compliance with Section 409A, to determine
whether an unforeseeable emergency exists, the amount reasonably necessary to satisfy the emergency need, and other related matters, taking into account the extent to which the hardship is or may be
relieved through any additional compensation that is available as the result of cancelling the participant's deferral election, reimbursement or compensation from insurance or otherwise, or by
liquidation of the participant's assets (to the extent the liquidation of such assets would not itself cause severe financial hardship). Hardship distributions are not permitted from a participant's
stock account. 

        3.8    Termination of Service.    Termination of Service means the date on which a participant has a "separation from
service" (as defined at Treas. Reg. Section 1.409A-1(h)), including by reason of death, from Genzyme and from all other corporations and trades or businesses, if any, that would be
treated as a single "service recipient" with Genzyme under Treas. Reg. Section 1.409A-1(h)(3). 

 ARTICLE IV  

 AMENDMENT AND TERMINATION  

        4.1    Amendment.    Genzyme may, without the consent of any participant, beneficiary or other person, amend the plan
at any time and from time to time. No amendment may reduce the amount credited to the deferral account of any participant. Any amendment that would cause a material modification of a benefit or right
existing as of October 4, 2004 and would result in a material benefit enhancement or addition affecting compensation earned and vested before January 1, 2005 will be ineffective and
rescinded before the earlier of the date the right is exercised (if the right is discretionary) or the last day of the calendar year during which the amendment is made. 

        4.2    Plan Termination.    Genzyme may terminate the plan at any time. 

        (a)    Compensation Earned Before January 1, 2005.    Upon termination of the plan, payments from that portion
of a participant's deferral account attributable to deferrals of compensation earned prior to January 1, 2005 will be made in the manner and at the time prescribed in Article III, except
that Genzyme may, in its discretion, distribute a participant's deferral account in a lump sum as soon as practicable after the date the plan is terminated. 

        (b)    Compensation Earned On or After January 1, 2005.    Genzyme may, in its discretion, distribute that
portion of a participant's deferral account attributable to deferrals of compensation earned on or after January 1, 2005 in a single lump sum payment within 30 days after the date the
plan is terminated and liquidated under one of the following circumstances, in accordance with Treas. Reg. Section 1.409A-3(j)(4)(ix): 

          (i)  Genzyme's
termination and liquidation of the plan within 12 months of a corporate dissolution taxed under Code Section 331, or with the approval of a
bankruptcy court pursuant to 11 U.S.C. § 503(b)(1)(A), provided that amounts deferred under the plan are included in the participant's gross income in the calendar year in which the
plan termination and liquidation occurs, or
if later, the first calendar year in which the payment is administratively practicable provided the payment was not constructively received in an earlier year; 

         (ii)  the
Company's termination and liquidation of the plan pursuant to an irrevocable action to terminate and liquidate the plan taken by Genzyme within 30 days
before or 12 months after a change in control event as defined in Treas. Reg. Section 1.409A-3(i)(5), provided that all other plans sponsored by the Company that are treated
as a single plan under Treas. Reg. Section 1.409A-1(c)(2) are similarly terminated and liquidated with respect to each participant that experienced the change in control event, with
the result that all such participants are required to receive all amounts deferred under all such other plans sponsored by the Company within 12 months of the date that the Company irrevocably
takes all necessary steps to terminate and liquidate all such other plans; or 

        (iii)  Genzyme's
termination and liquidation of the plan, provided the termination and liquidation is not proximate to a downturn in the Company's financial health, all other
plans of the same type (as defined under Treas. Reg. Section 1.409A-1(c)) sponsored by the Company are similarly terminated and liquidated, payments contingent upon the irrevocable
termination and liquidation of the plan are made after 12 months and within 24 months of the date of completion of all corporate actions for such termination, and a new plan that would
be aggregated with any terminated and liquidated plan under Treas. Reg. Section 1.409A-1(c) is not adopted by the Company at any time within 3 years of the date of completion
of these corporate actions. 

        For
purposes of Section 4.2(b), the "Company" means the service recipient as defined under Treas. Reg. Section1.409A-1(g), generally meaning Genzyme and all
corporations within Genzyme's controlled group of corporations under Code Section 414(b) and all partnerships and affiliates of Genzyme within 

common
control as defined under Code Section 414(c). For purposes of (ii) above, however, the identity of the Company will be determined immediately after the change in control event. 

Adopted
by directors on March 14, 1996

Approved by shareholders on May 16, 1996

Restated to reflect 2:1 stock split of the General Stock on July 25, 1996

Amended and restated by directors on January 30, 1997

Amended and restated by directors on March 24, 1999

Approved by stockholders on May 26, 1999

Amended and restated by directors on March 2, 2000

Restated to reflect 2:1 stock split of Genzyme General Stock on 6/1/01

Amended by directors on June 30, 2003

Amended by compensation committee of board of directors on August 22, 2007

Amended by compensation committee of board of directors on December 1, 2008 

QuickLinks

Exhibit 10.16

GENZYME CORPORATION DIRECTORS' DEFERRED COMPENSATION PLAN

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00154-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00154-of-00352.parquet"}]]